{"result": "(\"entity\"<|>MELAS<|>EVENT<|>Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) is a genetic disorder characterized by a range of neurological and muscular symptoms, including seizures and muscle weakness.)\n##\n(\"entity\"<|>L-CARNITINE<|>ORGANIZATION<|>L-carnitine is a nutrient that plays a crucial role in the metabolism of fatty acids and is used to improve energy production in cells.)\n##\n(\"entity\"<|>COENZYME Q10<|>ORGANIZATION<|>Coenzyme Q10 is a substance that helps generate energy in cells and has antioxidant properties, potentially beneficial for muscle weakness and fatigue.)\n##\n(\"entity\"<|>ARGININE<|>ORGANIZATION<|>Arginine is an amino acid that is involved in various metabolic processes and is used in the treatment of certain medical conditions.)\n##\n(\"entity\"<|>CLOPIDOGREL<|>ORGANIZATION<|>Clopidogrel is a medication used to prevent blood clots in patients with cardiovascular diseases.)\n##\n(\"entity\"<|>LACOSAMIDE<|>ORGANIZATION<|>Lacosamide is an anticonvulsant medication used to treat epilepsy.)\n##\n(\"entity\"<|>RANITIDINE<|>ORGANIZATION<|>Ranitidine is a medication that reduces stomach acid and is used to treat conditions like gastritis.)\n##\n(\"entity\"<|>LEVETIRACETAM<|>ORGANIZATION<|>Levetiracetam is an anticonvulsant medication used to treat seizures.)\n##\n(\"entity\"<|>LAMOTRIGINE<|>ORGANIZATION<|>Lamotrigine is an anticonvulsant medication used to treat epilepsy and bipolar disorder.)\n##\n(\"entity\"<|>DOMPERIDONE<|>ORGANIZATION<|>Domperidone is a medication used to relieve nausea and vomiting.)\n##\n(\"entity\"<|>LACTITOL<|>ORGANIZATION<|>Lactitol is a laxative used to treat constipation.)\n##\n(\"entity\"<|>29-YEAR-OLD WOMAN<|>PERSON<|>A 29-year-old woman diagnosed with MELAS, experiencing multiple health issues including seizures, nausea, and muscle weakness.)\n##\n(\"entity\"<|>MICROADENOMA<|>ORGANIZATION<|>A microadenoma is a small benign tumor of the pituitary gland that can cause hormonal imbalances.)\n##\n(\"entity\"<|>BROMOCRIPTINE<|>ORGANIZATION<|>Bromocriptine is a medication used to treat various conditions, including hyperprolactinemia and Parkinson's disease.)\n##\n(\"relationship\"<|>29-YEAR-OLD WOMAN<|>MELAS<|>The 29-year-old woman has been diagnosed with MELAS, which is the primary condition affecting her health<|>10)\n##\n(\"relationship\"<|>29-YEAR-OLD WOMAN<|>L-CARNITINE<|>The 29-year-old woman is undergoing treatment that includes L-carnitine to potentially improve her condition<|>8)\n##\n(\"relationship\"<|>29-YEAR-OLD WOMAN<|>COENZYME Q10<|>The 29-year-old woman is taking Coenzyme Q10 as part of her chronic treatment regimen<|>8)\n##\n(\"relationship\"<|>29-YEAR-OLD WOMAN<|>ARGININE<|>The 29-year-old woman is receiving arginine as part of her treatment for her condition<|>8)\n##\n(\"relationship\"<|>29-YEAR-OLD WOMAN<|>CLOPIDOGREL<|>The 29-year-old woman is prescribed clopidogrel to prevent blood clots due to her medical history<|>6)\n##\n(\"relationship\"<|>29-YEAR-OLD WOMAN<|>LACOSAMIDE<|>The 29-year-old woman is taking lacosamide to manage her seizures<|>8)\n##\n(\"relationship\"<|>29-YEAR-OLD WOMAN<|>RANITIDINE<|>The 29-year-old woman is prescribed ranitidine to manage her gastritis symptoms<|>6)\n##\n(\"relationship\"<|>29-YEAR-OLD WOMAN<|>LEVETIRACETAM<|>The 29-year-old woman is taking levetiracetam as part of her epilepsy treatment<|>8)\n##\n(\"relationship\"<|>29-YEAR-OLD WOMAN<|>LAMOTRIGINE<|>The 29-year-old woman is prescribed lamotrigine to help control her seizures<|>8)\n##\n(\"relationship\"<|>29-YEAR-OLD WOMAN<|>DOMPERIDONE<|>The 29-year-old woman is taking domperidone to alleviate her nausea<|>7)\n##\n(\"relationship\"<|>29-YEAR-OLD WOMAN<|>LACTITOL<|>The 29-year-old woman is using lactitol to manage her constipation<|>6)\n##\n(\"relationship\"<|>29-YEAR-OLD WOMAN<|>MICROADENOMA<|>The 29-year-old woman has a history of a microadenoma that was treated with bromocriptine<|>5)\n##\n(\"relationship\"<|>29-YEAR-OLD WOMAN<|>BROMOCRIPTINE<|>The 29-year-old woman was treated with bromocriptine for her microadenoma<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: de electrones, aportando un efecto antioxidante protector que podría tener efectos beneficiosos en la debilidad muscular, la fatiga y los niveles de lactato en algunos pacientes con esta enfermedad25. CoQ10 no cruza la barrera hematoencefálica por lo que tiene un efecto limitado en el sistema nervioso central. La idebenona en un análogo del CoQ10 que puede cruzar esta barrera y ha demostrado mejorar las complicaciones neurológicas en algunas series de casos26.\n\n- **L-carnitina**: es necesaria para la entrada de los ácidos grasos a la matriz mitocondrial donde se produce la beta oxidación. Por ello, la L-carnitina puede potencialmente mejorar la beta oxidación y reponer el pool intracelular de coenzima A17.\n\n- **Creatina**: se metaboliza a fosfocreatina, un donante esencial de fosfato para la regeneración de ATP en el músculo y en el cerebro, lo que mejora la fuerza muscular en el ejercicio en el síndrome de MELAS27,28.\n---\n# Caso clínico\n\nMujer de 29 años de edad, ingresada por crisis convulsivas repetidas generalizadas, e historia de somnolencia, náuseas, vómitos y estreñimiento.\n\nEntre sus antecedentes destacaba un síndrome de MELAS diagnosticado en 2008 (mutación 3246A>G) con clínica heterogénea;\n\n- Neurológico: migrañas, hipoacusia neurosensorial, epilepsia parcial compleja con generalización secundaria, miopatía, retraso psicomotor y lesiones bilaterales parieto-temporal-occipitales tipo ictus-like con clínica fundamentalmente visual.\n\n- Endocrino: baja talla en la infancia, hiperprolactinemia sintomática y microadenoma hipofisario de 3mm resuelto con tratamiento con bromocriptina desde 2006 a 2009, hipogonadismo hipogonadotropo persistente y bajo peso.\n\n- Digestivo: epigastralgia con estudio endoscópico compatible con gastritis atrófica, pólipos múltiples y episodios recurrentes de nauseas, vómitos y alteración del hábito intestinal que oscila entre diarrea y estreñimiento.\n\nLa paciente había tenido ingresos cada 6 meses desde 2006 por deterioro neurológico y crisis epilépticas por mal cumplimiento del tratamiento debido a las náuseas y vómitos.\n\nOtros antecedentes familiares: madre portadora de la mutación A243G y como manifestaciones presentaba DM, hipoacusia neurosensorial, hiperprolactinemia y sobrepeso grado 2.\n\nLa situación basal de la paciente era de dependencia para actividades basales de la vida diaria.\n\nEl tratamiento crónico consistía en arginina (1 sobre de 7 gramos diluido en 250 cc de agua cada 12 horas), L-carnitina (10 ml al día), coenzima Q10 (2 comprimidos de 50 mg cada ocho horas), clopidogrel (75 mg cada 24 horas), lacosamida (200 mg cada 12 horas), ranitidina (150 mg cada 12 horas), levetiracetam (1000 mg cada 12 horas), lamotrigina (100 mg cada 12 horas), domperidona (10 ml antes de cada comida) y si estreñimiento lactitol.\n\nOtros datos de la historia clínica se pueden ver en las Tablas 2 y 3.\n---\n## Tablas 2 y 3. Exploración física y pruebas complementarias al ingreso\n\n| Glu 134 mg/dl (74-106)                | NRL: Somnolienta. Glasgow 9                |\n| Urea 51 mg/dl (15-46)                 | Hipotonía generalizada. No                 |\n| Cr 0.73 (0.5-1.1)                     | asimetría facial. ROT: normales            |\n| Na 139 (132-146)                      | excepto rotulianos y aquíleos.             |\n| K 3.5 (3.5-5.5)                       | Sensibilidad, coordinación y               |\n| CPK 129                               | marcha no explorables.                     |\n| Mioglobina 74                         | Cardiorespiratorio: Rítmico y sin          |\n| PCR 3.2                               | soplos. MVC sin alteraciones.              |\n| Anormal y sedimentos: normal.         | Abdomen: Blando y depresible               |\n| Metilcetona +.                        | ruidos intestinales aumentados. No         |\n| Hb 15.6 gr/dl (12-16)                 | defensa ni irritación peritoneal.          |\n| Htco 31.2 % (36-46)                   | MMII: sin edemas. Pulsos pedios            |\n| Leucocitos 29.18 (4.5-11*10⁹)         | palpables y simétricos.                    |\n| (N 95,2%, L2.4%)\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}